Cargando…

New Immunohistochemical Markers for Pleural Mesothelioma Subtyping

Pleural mesothelioma (PM) comprises three main subtypes: epithelioid, biphasic and sarcomatoid, which have different impacts on prognosis and treatment definition. However, PM subtyping can be complex given the inter- and intra-tumour morphological heterogeneity. We aim to use immunohistochemistry (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Di Stefano, Iosè, Alì, Greta, Poma, Anello Marcello, Bruno, Rossella, Proietti, Agnese, Niccoli, Cristina, Zirafa, Carmelina Cristina, Melfi, Franca, Mastromarino, Maria Giovanna, Lucchi, Marco, Fontanini, Gabriella
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10529020/ https://www.ncbi.nlm.nih.gov/pubmed/37761312 http://dx.doi.org/10.3390/diagnostics13182945

Ejemplares similares

Gene Expression Analysis of Biphasic Pleural Mesothelioma: New Potential Diagnostic and Prognostic Markers
por: Bruno, Rossella, et al.
Publicado: (2022)

Prevalence of Delta-Like Protein 3 in a Consecutive Series of Surgically Resected Lung Neuroendocrine Neoplasms
por: Alì, Greta, et al.
Publicado: (2021)

Different pathological response and histological features following neoadjuvant chemotherapy or chemo-immunotherapy in resected non-small cell lung cancer
por: Alì, Greta, et al.
Publicado: (2023)

Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis
por: Bruno, Rossella, et al.
Publicado: (2016)

SMARCA4 as a support for the differential diagnosis of poorly differentiated lung carcinomas
por: Panozzi, Martina, et al.
Publicado: (2023)

Whole transcriptome targeted gene quantification provides new insights on pulmonary sarcomatoid carcinomas
por: Alì, Greta, et al.
Publicado: (2019)

New Insights in Pleural Mesothelioma Classification Update: Diagnostic Traps and Prognostic Implications
por: Mastromarino, Maria Giovanna, et al.
Publicado: (2022)

Editorial: Advances in malignant pleural mesothelioma: Diagnosis, treatment, and molecular mechanisms
por: Mastromarino, Maria Giovanna, et al.
Publicado: (2023)

Biomarkers and Gene Signatures to Predict Durable Response to Pembrolizumab in Non-Small Cell Lung Cancer
por: Poma, Anello Marcello, et al.
Publicado: (2021)

Role of microRNA-33a in regulating the expression of PD-1 in lung adenocarcinoma
por: Boldrini, Laura, et al.
Publicado: (2017)

Thoracic redo-robotic surgery (TRRS): a case series of a single centre
por: Ricciardi, Sara, et al.
Publicado: (2020)

Robotic versus Open Surgery in Locally Advanced Non-Small Cell Lung Cancer: Evaluation of Surgical and Oncological Outcomes
por: Zirafa, Carmelina C., et al.
Publicado: (2023)

Prognostic role of TPL2 in early-stage non-small cell lung cancer
por: Boldrini, Laura, et al.
Publicado: (2017)

Intraoperative Catastrophes during Robotic Lung Resection: A Single-Center Experience and Review of the Literature
por: Manfredini, Beatrice, et al.
Publicado: (2023)

Hyperthermic Intrathoracic Chemotherapy for Malignant Pleural Mesothelioma: The Forefront of Surgery-Based Multimodality Treatment
por: Aprile, Vittorio, et al.
Publicado: (2021)

Hippo pathway affects survival of cancer patients: extensive analysis of TCGA data and review of literature
por: Poma, Anello Marcello, et al.
Publicado: (2018)

The Role of Lymphadenectomy in Early-Stage NSCLC
por: Manfredini, Beatrice, et al.
Publicado: (2023)

Inflammatory Profiles of Tracheal Biopsies From SARS-CoV-2 Patients
por: Fiacchini, Giacomo, et al.
Publicado: (2022)

P2X7 mRNA expression in non-small cell lung cancer: MicroRNA regulation and prognostic value
por: BOLDRINI, LAURA, et al.
Publicado: (2015)

Treatment with interleukin-2 in malignant pleural mesothelioma: immunological and angiogenetic assessment and prognostic impact
por: Alì, G, et al.
Publicado: (2009)

Response to erlotinib in a patient with lung adenocarcinoma harbouring the EML4-ALK translocation: A case report
por: ALÌ, GRETA, et al.
Publicado: (2015)

Robotic Surgery for Non-Small Cell Lung Cancer Treatment in High-Risk Patients
por: Zirafa, Carmelina Cristina, et al.
Publicado: (2021)

Expression profiling and microRNA regulation of the LKB1 pathway in young and aged lung adenocarcinoma patients
por: Boldrini, Laura, et al.
Publicado: (2018)

Expression of miRNA-25 in young and old lung adenocarcinoma
por: Boldrini, Laura, et al.
Publicado: (2021)

Hyperthermic intrathoracic chemotherapy (HITHOC) should be included in the guidelines for malignant pleural mesothelioma
por: Migliore, Marcello, et al.
Publicado: (2021)

Clinical significance of histologic subtyping of malignant pleural mesothelioma
por: Brcic, Luka, et al.
Publicado: (2020)

Interobserver Agreement in Histopathological Subtyping of Malignant Pleural Mesotheliomas
por: Mlika, Mona, et al.
Publicado: (2021)

The italian consensus for the classification and reporting of thyroid cytology: Cytohistologic and molecular correlations on 37,371 nodules from a single institution
por: Torregrossa, Liborio, et al.
Publicado: (2022)

Predictive Biomarkers in Thyroid Cancer
por: Macerola, Elisabetta, et al.
Publicado: (2022)

Limited Accuracy of Pan-Trk Immunohistochemistry Screening for NTRK Rearrangements in Follicular-Derived Thyroid Carcinoma
por: Macerola, Elisabetta, et al.
Publicado: (2022)

Define the Two Molecular Subtypes of Epithelioid Malignant Pleural Mesothelioma
por: Saddozai, Umair Ali Khan, et al.
Publicado: (2022)

Molecular Alterations in Relation to Histopathological Characteristics in a Large Series of Pediatric Papillary Thyroid Carcinoma from a Single Institution
por: Macerola, Elisabetta, et al.
Publicado: (2021)

Clinical–Pathological Features and Treatment Outcome of Patients With Hobnail Variant Papillary Thyroid Carcinoma
por: Poma, Anello Marcello, et al.
Publicado: (2022)

Highlighting the immunohistochemical differences of malignant mesothelioma subtypes via case presentations
por: Sejben, Anita, et al.
Publicado: (2023)

Response to Letter to the Editor From Green and Gosmanov: “Tall Cell Percentage Alone in PTC Without Aggressive Features Should not Guide Patients’ Clinical Management”
por: Viola, David, et al.
Publicado: (2022)

Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma
por: Watanabe, Takuya, et al.
Publicado: (2018)

Comparative proteomic analysis of malignant pleural mesothelioma: Focusing on the biphasic subtype
por: Giusti, Laura, et al.
Publicado: (2016)

Squamous cell transformation and EGFR T790M mutation as acquired resistance mechanisms in a patient with lung adenocarcinoma treated with a tyrosine kinase inhibitor: A case report
por: Bruno, Rossella, et al.
Publicado: (2017)

Management of Pleural Effusion Secondary to Malignant Mesothelioma
por: Musso, Valeria, et al.
Publicado: (2021)

Malignant pleural mesothelioma
por: Rao, Sukhesh
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_88eio3nps0noqk5d3bp1ch9fvh